{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01).","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_3","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_4","claim":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_5","claim":"`fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_6","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_7","claim":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_8","claim":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]}]}